Glimepiride Bristol Laboratories

Glimepiride Bristol Laboratories is a prescription medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent, supplied in oral tablet form for the European market. It works by stimulating insulin release from pancreatic beta cells, helping to lower elevated blood glucose levels in patients with type 2 diabetes mellitus. The product is regulated as a prescription‑only drug and does not have a controlled substance schedule.

Glimepiride Bristol Laboratories is indicated for the management of hyperglycemia in adults with type 2 diabetes mellitus, typically as an adjunct to diet and exercise.

- Monotherapy in patients who cannot achieve glycemic control with diet and exercise alone. - Combination therapy with metformin or other oral antidiabetic agents when additional glucose lowering is needed. - Use in patients with stable renal function where sulfonylurea therapy is appropriate. - May be considered in patients who require a once‑daily oral agent to improve adherence.

The safety profile of glimepiride includes a range of observed adverse events, which are categorized by frequency and clinical significance.

Common: - Low blood sugar (hypoglycemia), especially when meals are missed or dosing is excessive. - Weight gain due to increased insulin activity. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Skin reactions like rash or pruritus.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including angioedema or Stevens‑Johnson syndrome. - Hepatotoxicity manifested by elevated liver enzymes. - Hematologic abnormalities such as leukopenia or thrombocytopenia.

When prescribing glimepiride, clinicians should evaluate several precautionary factors to minimize risk and ensure appropriate use.

- Assess renal and hepatic function before initiation and monitor periodically. - Use caution in elderly patients due to increased susceptibility to hypoglycemia. - Avoid use during pregnancy and lactation; the safety profile is not established. - Review concomitant medications that may potentiate hypoglycemia, such as beta‑blockers or other sulfonylureas. - Adjust dose in patients with a history of cardiovascular disease or heart failure. - Counsel patients on recognizing signs of hypoglycemia and the importance of regular meals.

Glimepiride can interact with other medicines, affecting its glucose‑lowering effect or increasing the risk of adverse reactions.

Avoid: - Other sulfonylureas or meglitinides, which may cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels. - High‑dose salicylates that may potentiate hypoglycemic action.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - ACE inhibitors or angiotensin receptor blockers, which may enhance insulin sensitivity. - Thiazide diuretics, which can affect glucose metabolism. - Alcohol consumption, which may increase hypoglycemia risk.